Supplemental Figure 1. Patient flow diagram.

3742 patients screened

2671 patients enrolled

Exposed population set: 2609 patients
  Received ≥1 anti-VEGF injection

Effectiveness analysis set: 2227 patients
  Received ≥1 anti-VEGF injection
  Had ≥1 visual acuity assessment for treated eye
  at baseline and ≥1 post-baseline assessment
  of visual acuity for the treated eye

First year completers' set: 1695 patients
  As effectiveness analysis set and for whom at least
  one year after first injection was documented

Second year completers' set: 1184 patients
  As effectiveness analysis set and for whom at least
  2 years after first injection was documented
Supplemental Figure 2. Baseline visual acuity score by country. The diamond represents the median; the upper and lower limits of the box represent the 75th and 25th percentiles, respectively, and the whiskers represent the 95th and 5th percentiles.
Supplementary Figure 3. LOCF analysis compared with observed values for the effectiveness analysis set (A), the first year completers’ set (B) and the second year completers’ set (C). LOCF, last observation carried forward.